COMP <GO>
BVS vs AORT // DIVIDEND YIELD & FCF PAYOUT SAFETY
Bioventus Inc. (Class A) (NASDAQ) VS. Artivion Inc. (NYSE) • 15-METRIC TALLY: BVS 7
— AORT 5
■ METRIC PARITY
LAST: $13.15 (-1.31%) • MKT CAP: $1.12B
dividend-safety
0.00%
LAST: $23.58 (+4.43%) • MKT CAP: $1.10B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BVS VS. AORT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BVS | AORT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 68.30% | 64.40% | +3.90 | BVS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.40% | 4.50% | +5.90 | BVS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.3x | 19.3x | +7.00 | AORT | /valuation <GO> |
| Free Cash Flow Yield | 5.77% | 0.07% | +5.70 | BVS | /fcf-yield <GO> |
| Operating Margin | 9.50% | 7.60% | +1.90 | BVS | /operating-margins <GO> |
| Net Profit Margin | 4.00% | 2.20% | +1.80 | BVS | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 13.60% | -14.50 | AORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 2.46 | -0.21 | AORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | AORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 47.0 | -1.30 | AORT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 51.2x | 98.3x | -47.10 | BVS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.12B | $1.10B | $19.6M | BVS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BVS REV | AORT REV | BVS GROSS % | AORT GROSS % | BVS FCF | AORT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $568.1M | $441.3M | 68.3% | 64.4% | $72.1M | $839.0K |
| FY 2024 | $573.3M | $388.5M | 67.7% | 64.0% | $37.8M | $11.0M |
| FY 2023 | $512.3M | $354.0M | — | — | $15.3M | $18.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BVS // BETA —
AORT // BETA —